Rhumbline Advisers Gemini Therapeutics, Inc. Transaction History

Rhumbline Advisers

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.22 - $1.73 $21,110 - $29,935	-17,304 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.29 - $3.08 $1,849 - $4,416	-1,434 Reduced 7.65%	17,304 $24,000
Q3 2021 Nov 12, 2021	SELL	$3.3 - $6.32 $2,125 - $4,070	-644 Reduced 3.32%	18,738 $76,000
Q2 2021 Aug 05, 2021	BUY	$6.32 - $14.02 $122,494 - $271,735	19,382 New	19,382 $125,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.